Abbvie Inc

-1.02 (-0.77%)
4:30:22 PM EDT: $131.91 -0.10 (-0.08%)
Products, Regulatory

Abbvie Says Upadacitinib Achieved Primary And Key Secondary Endpoints In First Phase 3 Induction Study In Patients With Crohn's Disease

Published: 12/06/2021 15:28 GMT
Abbvie Inc (ABBV) - Upadacitinib (rinvoq®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients With Crohn's Disease.
Abbvie Inc - Significantly Higher Proportion of Upadacitinib-treated Patients Achieved Steroid-free Clinical Remission at Week 12 Compared to Placebo.
Abbvie Inc - Safety Results in Study Were Consistent With Known Profile of Upadacitinib, With No New Safety Risks Observed.
Abbvie Inc - Upadacitinib (45 Mg Once Daily) Achieved Both Primary Endpoints of Clinical Remission and Endoscopic Response at Week 12.